Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
1998-4-29
pubmed:abstractText
The experience with 52 episodes of visceral leishmaniasis diagnosed in 43 patients is reported. The most common symptoms were fever (81%), splenomegaly (65%), hepatomegaly (63%), and pancytopenia (73%). In 79% of the patients, CD4+ cell counts were < 100 cells/mm3. Prior or simultaneous diagnosis of AIDS was made in 29 (67%) patients. Diagnosis was considered fortuitous in 19% of the episodes. In 27% of the episodes, the diagnosis was made on the basis of demonstration of parasites outside the reticuloendothelial system, chiefly blood (7 cases) and gastrointestinal mucosa (5 cases). Parasites were frequently observed or cultured from blood (22/37 episodes) or the digestive tract (8/9 episodes). High antimony doses were more effective than low doses in achieving clinical or parasitological cure (rate of cure, 80% vs. 40%, p = 0.11). Severe toxicity was observed in six (11.7%) of the 51 treated episodes. Severe AIDS-related diseases [odds ratio (OR) 10, p < 0.05] and CD4+ counts (OR 12, p < 0.05) were independent factors for early death. Prophylaxis with monthly pentamidine was not useful in reducing relapses of visceral leishmaniasis.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0934-9723
pubmed:author
pubmed:issnType
Print
pubmed:volume
16
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
898-903
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:9495670-AIDS-Related Opportunistic Infections, pubmed-meshheading:9495670-Allopurinol, pubmed-meshheading:9495670-Amebicides, pubmed-meshheading:9495670-Amphotericin B, pubmed-meshheading:9495670-Analysis of Variance, pubmed-meshheading:9495670-Anti-HIV Agents, pubmed-meshheading:9495670-Antimetabolites, pubmed-meshheading:9495670-Antimony, pubmed-meshheading:9495670-Antiprotozoal Agents, pubmed-meshheading:9495670-Blood, pubmed-meshheading:9495670-Bone Marrow, pubmed-meshheading:9495670-CD4-Positive T-Lymphocytes, pubmed-meshheading:9495670-Cerebrospinal Fluid, pubmed-meshheading:9495670-Didanosine, pubmed-meshheading:9495670-Digestive System, pubmed-meshheading:9495670-Dose-Response Relationship, Drug, pubmed-meshheading:9495670-Drug Therapy, Combination, pubmed-meshheading:9495670-Female, pubmed-meshheading:9495670-Follow-Up Studies, pubmed-meshheading:9495670-HIV, pubmed-meshheading:9495670-Hepatic Encephalopathy, pubmed-meshheading:9495670-Humans, pubmed-meshheading:9495670-Intestinal Mucosa, pubmed-meshheading:9495670-Leishmaniasis, Visceral, pubmed-meshheading:9495670-Lymphocyte Count, pubmed-meshheading:9495670-Male, pubmed-meshheading:9495670-Myocarditis, pubmed-meshheading:9495670-Neutrophils, pubmed-meshheading:9495670-Pancreatitis, pubmed-meshheading:9495670-Pentamidine, pubmed-meshheading:9495670-Renal Insufficiency, pubmed-meshheading:9495670-Spain, pubmed-meshheading:9495670-Zidovudine
pubmed:year
1997
pubmed:articleTitle
Visceral leishmaniasis in patients infected with the human immunodeficiency virus.
pubmed:affiliation
Servicio de Enfermedades Infecciosas, Centro Nacional de Investigación Clínica, Instituto de Salud Carlos III, Madrid, Spain.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't